SAN JOSE, Calif.--(BUSINESS WIRE)-- Nodexus Inc., an emerging leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that William (Bill) Rhodes has been named Executive Chairman of the company’s Board of Directors. Rhodes has served on the Nodexus Board as an Independent Director since 2021 and was previously an Advisor to the company.

“We are thrilled to increase Bill’s involvement in his new role as Executive Chairman,” said Karthik Balakrishnan, PhD, Founder and CEO of Nodexus. “His extensive experience in the life sciences industry and his strategic insights continue to be instrumental in helping build Nodexus. Bill’s guidance will further position us for the next phase of growth focused on expanding our commercial footprint and delivering value to our current and future customers who seek affordable and easy-to-use enabling tools to power their biological workflows.”

Rhodes is a veteran executive with extensive experience in the diagnostics and life science tools markets. During his sixteen-year career at Becton, Dickinson and Co. (BD), he served as BD’s Senior Vice President of Corporate Strategy and Development and Worldwide President of BD Biosciences, a $1.4B business unit that included Cell Analysis, Discovery Labware, and Advanced Bioprocessing. Rhodes was also responsible for creating BD Ventures, the venture capital arm of BD. Prior to BD, he held senior positions at Johnson & Johnson and Pfizer. Rhodes holds a Bachelor of Science degree from Cornell University and a Master’s degree in International Business from Seton Hall University. Rhodes currently sits on the Boards of both public and private medical and healthcare companies in the US, Belgium, and the UK, and has previously chaired life sciences and diagnostics companies in Germany and the Netherlands.

“It’s an honor to take on this new leadership role with Nodexus as we scale the commercial organization and expand on the exciting traction the company has already achieved, which spans broadly from large pharma to individual academic labs,” said Rhodes. “I strongly believe in the Nodexus mission to make single-cell workflows and gentle microfluidic isolation truly accessible to biological laboratories around the world. I look forward to working closely with the team to aid scientists advancing novel cell and gene-based biomedical and clinical research.”

About Nodexus

Nodexus is a life science tools company that develops platforms to accelerate biological workflows and make them widely accessible. The company leverages a proprietary technology suite consisting of contamination-free microfluidic cartridges, hardware instruments, and software offerings. Nodexus’ flagship NX One platform offers integrated, easy-to-use, and affordable automated cell isolation for applications in industry, clinical research, and academia, including cell line and antibody development, CRISPR engineering, single-cell genomics, synthetic biology, and more. For more information regarding the company and the NX One, please visit Nodexus.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318786087/en/